Research Paper Volume 12, Issue 17 pp 17694—17712
Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells
Figure 4. Doc increased the expression of MALAT1 in DocR- cells. (A–C) The RNA expression of MALAT1 (A) in DocS1_CWR22Rv1 and DocR1_CWR22Rv1 cells, (B) in DocS2_CWR22Rv1 and DocR2_CWR22Rv1 cells, (C) MALAT1 promoter activity in DocR3_C4-2 cells compared to DocS3_C4-2 cells. Results are mean ± SD compared to controls, *p<0.05; ***p<0.001.